Evidence map›Paper›PMID 38737643›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2024

Case report: [

Zehao Wang, Zheng Liu, Lulu Zhuang, Weihua Yin, Yongsheng Zhao, Mengjie Dong

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zehao WangDepartment of Nuclear Medicine, Peking University Shenzhen Hospital Shenzhen, Guangdong, China.
Zheng LiuDepartment of Nuclear Medicine, Peking University Shenzhen Hospital Shenzhen, Guangdong, China.
Lulu ZhuangDepartment of Medical Imaging, Peking University Shenzhen Hospital Shenzhen, Guangdong, China.
Weihua YinDepartment of Pathology, Peking University Shenzhen Hospital Shenzhen, Guangdong, China.
Yongsheng ZhaoDepartment of Nuclear Medicine, Peking University Shenzhen Hospital Shenzhen, Guangdong, China.
Mengjie DongDepartment of Nuclear Medicine, Peking University Shenzhen Hospital Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenoid cystic carcinoma (ACC) is a rare salivary gland cancer. Still, its growth and invasion progress is slow, and its hematogenous metastasis is ACC's most common distant metastasis. Because of the broad expression and low background uptake of fibroblast activation protein (FAP) in tumor stroma, FAPI is considered another potential tracer of ACC in addition to FDG. In this case, we report a patient who was diagnosed with metastatic ACC liver cancer by fine needle aspiration biopsy (FNAB) and underwent PET/CT examination of [

Indexed as

[18F]FAPI-42[18F]FDGadenoid cystic carcinomaliver metastase

Identifiers

PMID38737643
PMCPMC11087294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.